<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cancer Res Clin Oncol</journal-id><journal-id journal-id-type="iso-abbrev">J Cancer Res Clin Oncol</journal-id><journal-title-group><journal-title>Journal of Cancer Research and Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">0171-5216</issn><issn pub-type="epub">1432-1335</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39888414</article-id><article-id pub-id-type="pmc">PMC11785664</article-id>
<article-id pub-id-type="publisher-id">6101</article-id><article-id pub-id-type="doi">10.1007/s00432-025-06101-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Belge</surname><given-names>Gazanfer</given-names></name><address><email>belge@uni-bremen.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Klemke</surname><given-names>Markus</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hansen</surname><given-names>Bendix</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Dumlupinar</surname><given-names>Cansu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Igde</surname><given-names>Aylin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Arnold</surname><given-names>Dirk</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Salwender</surname><given-names>Hans</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>W&#x000fc;lfing</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Soave</surname><given-names>Armin</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Dieckmann</surname><given-names>Klaus-Peter</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04ers2y35</institution-id><institution-id institution-id-type="GRID">grid.7704.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2297 4381</institution-id><institution>Department of Tumour Genetics, Faculty of Biology and Chemistry, </institution><institution>University of Bremen, </institution></institution-wrap>Bremen, Germany </aff><aff id="Aff2"><label>2</label>mir|detect GmbH, Bremerhaven, Germany </aff><aff id="Aff3"><label>3</label>Department of Urology, Asklepios Tumorzentrum Hamburg, AK Altona, Hamburg, Germany </aff><aff id="Aff4"><label>4</label>Department of Oncology, Asklepios Tumorzentrum Hamburg, AK Altona, Hamburg, Germany </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01zgy1s35</institution-id><institution-id institution-id-type="GRID">grid.13648.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 3484</institution-id><institution>Department of Urology, </institution><institution>University Medical Center Hamburg-Eppendorf, </institution></institution-wrap>Hamburg, Germany </aff></contrib-group><pub-date pub-type="epub"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>151</volume><issue>2</issue><elocation-id>58</elocation-id><history><date date-type="received"><day>2</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>14</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">microRNA-371a-3p (M371) is considered a highly sensitive and specific serum biomarker of testicular germ cell tumours (GCTs). However, little is known about the expression of M371 in nontesticular malignancies (NTMs), so far. As knowledge about the expression of the marker in other malignancies is a prerequisite for the clinical application of the test we aimed to explore the M371 expression in other cancers.</p></sec><sec><title>Methods</title><p id="Par2">M371 serum levels were measured in 137 patients with NTM of 12 different neoplastic entities using the IVDR-certified M371-Test for quantitative real-time PCR. Median M371 serum levels and percentages of M371 level elevations were calculated for the entire NTM group and for entity-specific subgroups. The results were compared with GCT patients (<italic>n</italic>&#x02009;=&#x02009;20) and with tumour-free male controls (<italic>n</italic>&#x02009;=&#x02009;20) using descriptive statistical methods.</p></sec><sec><title>Results</title><p id="Par3">Eight patients with NTMs had M371 serum level elevations, corresponding to a false-positive rate (FPR) of 5.84% (95% confidence intervals (CIs) 2.55&#x02013;11.18%). Expression rates in GCTs and controls were 100% and zero, respectively. Thus, the specificity of the M371-Test for GCT is 94.90% (95% CI 90.21&#x02013;97.77%) when all NTMs and tumour-free controls are considered. Remarkably, three out of 5 patients with multiple myeloma had elevated M371 levels.</p></sec><sec><title>Conclusion</title><p id="Par4">The false-positive rate of the M371-Test in other malignancies than GCT is very low, and almost identical with that in healthy males, corresponding to a high specificity of 94.9% for detection of GCT. The surprising finding of M371 elevations in patients with multiple myeloma needs further investigation.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Testicular germ cell tumour</kwd><kwd>Biomarker</kwd><kwd>microRNA-371a-3p</kwd><kwd>Multiple myeloma</kwd><kwd>Chromosome 19, test specificity</kwd></kwd-group><funding-group><award-group><funding-source><institution>Universit&#x000e4;t Bremen (1013)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">During the last decade, microRNAs (miRs) of the miR-371-373 cluster and their putative roles in the clinical management of testicular germ cell tumours (GCTs) have been extensively studied (Le&#x000e3;o et al. <xref ref-type="bibr" rid="CR12">2021</xref>; Seales et al. <xref ref-type="bibr" rid="CR20">2024</xref>). In particular, serum levels of microRNA-371a-3p (M371) were shown to feature many of the characteristics a valuable biomarker is supposed to have according to the criteria stipulated by Lange and Winfield in 1987 (Lange and Winfield <xref ref-type="bibr" rid="CR10">1987</xref>). M371 involves 90% sensitivity and &#x0003e;&#x02009;90% specificity for primary diagnosis of GCTs (Dieckmann et al. <xref ref-type="bibr" rid="CR3">2017a</xref>, <xref ref-type="bibr" rid="CR4">b</xref>). Likewise, relapses during surveillance of clinical stage 1 GCTs can safely be diagnosed (Lobo et al. <xref ref-type="bibr" rid="CR14">2021</xref>; Fankhauser et al. <xref ref-type="bibr" rid="CR6">2022</xref>; Belge et al. <xref ref-type="bibr" rid="CR1">2024</xref>), and the same is true for predicting histology of lymph nodes excised upon retroperitoneal lymph node dissection (Lafin et al. <xref ref-type="bibr" rid="CR8">2020</xref>; Seelemeyer et al. <xref ref-type="bibr" rid="CR21">2024</xref>). Also, the half-life of M371 after resection of GCT was shown to be less than 24&#x000a0;h (Radtke et al. <xref ref-type="bibr" rid="CR18">2018</xref>). Thus, M371 was considered to represent a novel and powerful serum biomarker of GCT eclipsing the traditional markers.</p><p id="Par6">However, in spite of the multitude of studies conducted to explore the features of M371, only very few investigations have addressed the condition #1 of the Lange &#x00026; Winfield list, i.e. the specification that the marker substance is only produced by the malignancy itself. Few reports documented the non-expression of M371 in testicular neoplasms of non-germ cell origin, such as sex cord gonadal stromal tumours, epidermoid cysts and malignant testicular lymphoma (Syring et al. <xref ref-type="bibr" rid="CR24">2015</xref>; van Agthoven and Looijenga <xref ref-type="bibr" rid="CR26">2017</xref>; Belge et al. <xref ref-type="bibr" rid="CR2">2020</xref>). Malignancies arising from other sites than the gonads have been evaluated in only one study to date (Spiekermann et al. <xref ref-type="bibr" rid="CR23">2015</xref>). That pilot study analysed 24 nontesticular malignancies and found zero expression of M371 in 12 cases but remarkably, it also noted traces of the miR in the other half of patients. Other studies revealed a physiological role of miR-371a-3p in regulating antiproliferative pathways via the TOB1 axis in colorectal and gastric cancer (Guo et al. <xref ref-type="bibr" rid="CR7">2019</xref>; Wang et al. <xref ref-type="bibr" rid="CR27">2020</xref>). Moreover, miRs of the miR-371-3a cluster have been found to be involved in molecular processes in tumorigenesis in various neoplastic diseases (Shah et al. <xref ref-type="bibr" rid="CR22">2021</xref>). Therefore, elevations of miR-371 serum levels in malignancies other than GCT are principally conceivable. Importantly, if elevations of M371 serum levels should be detectable in a relevant number of patients with other cancers, this finding could have a considerable bearing on the utility of M371 as biomarker of GCTs. To address this open issue, we analysed M371 serum levels in a large number of patients with various cancers and compared the results with measurements in both GCT patients and in healthy males.</p></sec><sec id="Sec2"><title>Patients, methods</title><sec id="Sec3"><title>Patients, controls</title><p id="Par7">Consecutive patients treated for nontesticular malignancies (NTMs) in the departments of haematology/ oncology and of urology in Asklepios Klinik Altona, Hamburg, during 2023&#x02013;2024 were included. Fifty-one (37%) patients were examined before the start of curative treatment. The remainder were under treatment at the time of examination but far from cure. So, all patients included in the study were loaded with significant tumour masses at the time of examination. Treatment consisted of surgery in most of the urological cancers and in testicular lymphomas while chemotherapy with various regimens was applied in all others. Patient age and histologic tumour type were registered in each case. For comparison two control groups were included, first, patients with histologically proven GCT clinical stage 1 treated in the department of urology in Asklepios Klinik Altona 2024, and second, tumour-free male controls seeking general health check in the same institution during 2023&#x02013;2024.</p><p id="Par8">Informed consent was obtained from all individual participants included in the study. The Ethical Committee of &#x000c4;rztekammer Bremen approved the study (HR/RE-301&#x000a0;A). All study activities followed the rules of the Declaration of Helsinki documented by the 64th General Assembly of the World Medical Association in October 2013.</p></sec><sec id="Sec4"><title>Laboratory methods</title><p id="Par9">Cubital vein whole-blood samples were processed to serum by centrifugation at 2,500&#x000a0;g /10 minutes. Serum aliquots were then stored at minus 80&#x000a0;&#x000b0;C until further processing. Measurement of levels of microRNA-371a-3p were performed as described earlier, using the IVDR- certified M371-Test (mir|detect, Bremerhaven, Germany) for quantitative real time polymerase chain reaction (qPCR) and with miR-30b-5p as endogenous control (Dieckmann et al. <xref ref-type="bibr" rid="CR5">2019</xref>). Results were obtained as relative quantities (RQ values) according to the &#x02206;&#x02206;Ct method (Livak and Schmittgen <xref ref-type="bibr" rid="CR13">2001</xref>). The standard cut-off used for primary diagnosis of GCTs, the value of RQ&#x02009;=&#x02009;5, was also employed as upper limit of norm in this evaluation.</p></sec><sec id="Sec5"><title>Statistical analysis</title><p id="Par10">Any M371 elevation above cut-off in NMT patients and controls was considered false-positive. Median values with interquartile ranges (IQRs) of M371 serum levels were calculated in GCT patients, healthy controls, in the entire group of NTMs, and in subgroups with specific neoplastic entities. Likewise, false-positive rates (FPR) with 95% confidence intervals (CIs) were calculated for each subgroup. Mann-Whitney U tests were performed to compare the relative expression (RQ-levels) of miR-371a-3p between subgroups and controls. Statistical significance was assumed at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. Statistical analysis was performed using IBM SPSS Statistics for Windows, Version 29.0.2.0 (IBM Corp., Armonk, NY).</p></sec></sec><sec id="Sec6"><title>Results</title><p id="Par11">A total of 137 patients with 12 different NTMs were included, thereof 84 genitourinary cancers (GUCs), 36 haematological malignancies, 11 melanomas, 4 gastrointestinal cancers, and 2 bronchial carcinomas. Control groups consisted of 20 GCT patients, clinical stage 1, and 20 tumour-free males (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Over-all, 8 patients (FPR: 5.84%; 95% CIs 2.55&#x02013;11.18%) with NTM were found to have M371 serum level elevations above cut-off, opposed to 100% in GCT patients and none in male controls. Tabulation of the separate measurement results of all malignant entities (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) revealed that each one elevation was found in melanoma (among 11); prostate carcinoma (among 27); renal cell carcinoma (among 17), and two elevations in urothelial carcinoma (among 32). Strikingly, 3 out of 5 patients with multiple myeloma had elevations (FPR: 60%). Most of the serum level elevations in NTMs were only of modest extent with RQ-values of 16.51&#x02013;59.97 (Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>). However, one case with multiple myeloma revealed a considerable elevation of RQ&#x02009;=&#x02009;50,920, surpassing even the highest values found in GCT patients (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). To rule out laboratory technical failures, all of the RQ-values in multiple myeloma were confirmed by remeasuring. In addition, all three cases with M371 elevations were re-examined clinically, to rule out an occult testicular tumour. Statistical comparisons of RQ-values of the various subgroups with that of GCTs revealed significant differences with regard to each of the malignant entities tested, except for the group of multiple myelomas. The specificity for GCTs of the M371-Test is 94.16% (95% CI 88.82&#x02013;97.45%) when the results of all malignancies other than germ cell tumours (<italic>n</italic>&#x02009;=&#x02009;137) are considered and it is 94.90% (95% CI 90.21&#x02013;97.77%) when all non-GCT samples, including tumour-free male controls (<italic>n</italic>&#x02009;=&#x02009;157) are taken into account.</p><p id="Par12">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Study population. Number and median age of patients included in study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Entity</th><th align="left">(<italic>n</italic>)</th><th align="left">Median age (years)</th><th align="left">IQR<break/>(years)</th></tr></thead><tbody><tr><td align="left">
<bold>Genitourinary cancers</bold>
</td><td align="left">84</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Prostate cancer</td><td align="left">27</td><td align="left">73.0</td><td align="left">69&#x02013;78</td></tr><tr><td align="left">&#x02003;Urothelial carcinoma</td><td align="left">32</td><td align="left">69.0</td><td align="left">60-79.75</td></tr><tr><td align="left">&#x02003;Renal cell cancer</td><td align="left">17</td><td align="left">62.0</td><td align="left">59-70.5</td></tr><tr><td align="left">&#x02003;Penile cancer</td><td align="left">3</td><td align="left">52.0</td><td align="left"/></tr><tr><td align="left">&#x02003;Spermatic cord sarcoma</td><td align="left">5</td><td align="left">60.0</td><td align="left">41-70.5</td></tr><tr><td align="left">
<bold>Haematological malignancies</bold>
</td><td align="left">36</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Testicular malignant lymphoma</td><td align="left">7</td><td align="left">62.0</td><td align="left">56&#x02013;68</td></tr><tr><td align="left">&#x02003;Hodgkin&#x000b4;s disease</td><td align="left">5</td><td align="left">49.0</td><td align="left">32.5&#x02013;73</td></tr><tr><td align="left">&#x02003;Non-Hodgkin Lymphoma</td><td align="left">19</td><td align="left">66.0</td><td align="left">54&#x02013;77</td></tr><tr><td align="left">&#x02003;Multiple myeloma</td><td align="left">5</td><td align="left">63.0</td><td align="left">47.5&#x02013;68</td></tr><tr><td align="left">
<bold>Malignant melanoma</bold>
</td><td align="left">11</td><td align="left">n. a.</td><td align="left">n. a.</td></tr><tr><td align="left">
<bold>Gastrointestinal carcinoma</bold>
</td><td align="left">4</td><td align="left">58.5</td><td align="left">33.25&#x02013;79.25</td></tr><tr><td align="left">
<bold>Bronchial carcinoma</bold>
</td><td align="left">2</td><td align="left">65.0</td><td align="left"/></tr><tr><td align="left">
<bold>Germ cell tumour</bold>
</td><td align="left">20</td><td align="left">33.5</td><td align="left">26.75&#x02013;40.75</td></tr><tr><td align="left">
<bold>Tumour-free male controls</bold>
</td><td align="left">20</td><td align="left">37.5</td><td align="left">28-51.75</td></tr></tbody></table><table-wrap-foot><p>n. a.: not available</p></table-wrap-foot></table-wrap>
</p><p id="Par13">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Study results. False-positive rates and median M371 serum levels in subgroups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Entity</th><th align="left">Total samples</th><th align="left">Elevated M371-levels</th><th align="left">FPR (%)</th><th align="left">Median RQ-value (range)</th></tr></thead><tbody><tr><td align="left">
<bold>Genitourinary cancers</bold>
</td><td align="left">
<bold>84</bold>
</td><td align="left">
<bold>4</bold>
</td><td align="left">
<bold>4.76</bold>
</td><td align="left">
<bold>-</bold>
</td></tr><tr><td align="left">&#x02003;Prostate cancer</td><td align="left">27</td><td align="left">1</td><td align="left">3.70</td><td align="left">0 (0.00&#x02013;25.20)</td></tr><tr><td align="left">&#x02003;Urothelial carcinoma</td><td align="left">32</td><td align="left">2</td><td align="left">6.25</td><td align="left">0 (0.00&#x02013;23.46)</td></tr><tr><td align="left">&#x02003;Renal cell cancer</td><td align="left">17</td><td align="left">1</td><td align="left">5.88</td><td align="left">0 (0.00&#x02013;16.51)</td></tr><tr><td align="left">&#x02003;Penile cancer</td><td align="left">3</td><td align="left">0</td><td align="left">0.00</td><td align="left">0.07 (0.00&#x02013;0.24)</td></tr><tr><td align="left">&#x02003;Spermatic cord sarcoma</td><td align="left">5</td><td align="left">0</td><td align="left">0.00</td><td align="left">0 (0.00&#x02013;0.00)</td></tr><tr><td align="left">
<bold>Haematological malignancies</bold>
</td><td align="left">
<bold>36</bold>
</td><td align="left">
<bold>3</bold>
</td><td align="left">
<bold>8.33</bold>
</td><td align="left">
<bold>-</bold>
</td></tr><tr><td align="left">&#x02003;Testicular malignant lymphoma</td><td align="left">7</td><td align="left">0</td><td align="left">0.00</td><td align="left">0 (0.00&#x02013;2.96)</td></tr><tr><td align="left">&#x02003;Hodgkin&#x000b4;s disease</td><td align="left">5</td><td align="left">0</td><td align="left">0.00</td><td align="left">0 (0.00&#x02013;0.12)</td></tr><tr><td align="left">&#x02003;Non-Hodgkin Lymphoma</td><td align="left">19</td><td align="left">0</td><td align="left">0.00</td><td align="left">0 (0.00&#x02013;0.96)</td></tr><tr><td align="left">&#x02003;Multiple myeloma</td><td align="left">5</td><td align="left">3</td><td align="left">60.00</td><td align="left">56.68 (0.00&#x02013;50,920.2)</td></tr><tr><td align="left">
<bold>Malignant melanoma</bold>
</td><td align="left">
<bold>11</bold>
</td><td align="left">
<bold>1</bold>
</td><td align="left">
<bold>9.09</bold>
</td><td align="left">
<bold>0 (0.00&#x02013;292.84)</bold>
</td></tr><tr><td align="left">
<bold>Gastrointestinal carcinoma</bold>
</td><td align="left">
<bold>4</bold>
</td><td align="left">
<bold>0</bold>
</td><td align="left">
<bold>0.00</bold>
</td><td align="left">
<bold>0.01 (0.00&#x02013;2.17)</bold>
</td></tr><tr><td align="left">
<bold>Bronchial carcinoma</bold>
</td><td align="left">
<bold>2</bold>
</td><td align="left">
<bold>0</bold>
</td><td align="left">
<bold>0.00</bold>
</td><td align="left">
<bold>0 (0.00&#x02013;0.00)</bold>
</td></tr><tr><td align="left">
<bold>Germ cell tumour</bold>
</td><td align="left">
<bold>20</bold>
</td><td align="left">
<bold>20</bold>
</td><td align="left">
<bold>n. a.</bold>
</td><td align="left">
<bold>367.17 (8.46&#x02013;8779.96)</bold>
</td></tr><tr><td align="left">
<bold>Tumour-free male controls</bold>
</td><td align="left">
<bold>20</bold>
</td><td align="left">
<bold>0</bold>
</td><td align="left">
<bold>0.00</bold>
</td><td align="left">
<bold>0.07 (0.00&#x02013;1.73)</bold>
</td></tr><tr><td align="left">
<bold>All malignancies except GCT</bold>
</td><td align="left">
<bold>137</bold>
</td><td align="left">
<bold>8</bold>
</td><td align="left">
<bold>5.84</bold>
</td><td align="left">
<bold>-</bold>
</td></tr><tr><td align="left">
<bold>All non-GCT samples</bold>
</td><td align="left">
<bold>157</bold>
</td><td align="left">
<bold>8</bold>
</td><td align="left">
<bold>5.10</bold>
</td><td align="left">
<bold>-</bold>
</td></tr></tbody></table><table-wrap-foot><p>FPR: false-positive rate</p></table-wrap-foot></table-wrap>
</p><p id="Par14">
<fig id="Fig1"><label>Fig. 1</label><caption><p>miR-371a-3p expression in testicular germ cell tumours, male controls and other malignancies. Median M371 expression in testicular germ cell tumours (GCTs) is significantly higher than that of controls and of each of the nontesticular malignancies. Box plot showing median miR-371a-3p expression (RQ value) in testicular germ cell tumours (GCTs), male controls and 137 other malignancies. The boxes display the first quartile, median and third quartile. The whiskers are defined as the largest or lowest observed value that falls within 1.5 times the interquartile range measured from Q3 or Q1. Mild outliers are represented by dots and extreme outliers by asterisks. The dashed grey line indicates the cut-off value (RQ&#x02009;=&#x02009;5). The y-axis is depicted in a logarithmic scale. Significant differences are indicated by bars above the groups, *** <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001. GUC: genitourinary cancers except GCT; HM: haematological malignancies; MEL: malignant melanomas; GIT: gastrointestinal tumours; BRO: bronchial carcinomas; C: tumour-free male controls</p></caption><graphic xlink:href="432_2025_6101_Fig1_HTML" id="d33e960"/></fig>
</p><p id="Par15">
<fig id="Fig2"><label>Fig. 2</label><caption><p>miR-371a-3p expression in serum of various subtypes of haematological malignancies in comparison to germ cell tumours and tumour-free male controls. Median M371 serum levels of patients with various subtypes of haematological malignancies are in the range of male controls and are significantly lower than the M371 level of testicular germ cell tumours. By contrast, no significant difference was observed between multiple myelomas and GCT. Box plot as outlined in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. Significant differences are indicated by bars above the groups, *** <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001. Extreme outliers are represented by asterisks. The dashed grey line indicates the cut-off value (RQ&#x02009;=&#x02009;5). Because of extreme variance of results, the data in multiple myelomas are not given in a box-whisker format but as dots representing individual RQ values. The y-axis is depicted in a logarithmic scale. MLT: malignant testicular lymphoma; HD: Hodgkin&#x000b4;s disease; NHL: Non-Hodgkin lymphoma; MM: multiple myeloma; GCT: testicular germ cell tumour; C: tumour-free male controls</p></caption><graphic xlink:href="432_2025_6101_Fig2_HTML" id="d33e977"/></fig>
</p></sec><sec id="Sec7"><title>Discussion</title><p id="Par16">The crucial result of the present study is that a small proportion of 5.8% of patients with a variety of malignant nontesticular tumours have elevated M371 serum levels. This result is widely in line with the pilot study of 2015 (Spiekermann et al. <xref ref-type="bibr" rid="CR23">2015</xref>). The finding of a 94.9% specificity calculated from the data of the present study, underlines the great utility of M371 as a highly specific serum biomarker of GCT.</p><p id="Par17">A rather startling finding is the high M371 expression in three patients with multiple myeloma. False-positive measurements can be ruled out because the RQ-values are rather high, in one case even higher than in GCT patients. Also, remeasurements confirmed the results precluding a technical failure. The underlying reasons for M371 expression in a high number of patients with multiple myeloma remain elusive. Statistical artifact based on the small number has to be taken into account, but again, this assumption is unlikely because of the rather high M371 levels found in these patients. Putatively, cytogenetic anomalies frequently encountered in multiple myeloma might represent the clue for understanding the unexpected finding. Cytogenetic analyses have revealed structural changes of chromosomes in 51% of cases with multiple myeloma (La&#x000ef; et al. <xref ref-type="bibr" rid="CR9">1995</xref>). Chromosomal disorders involve losses of chromosomal material and also gains which may occur on several chromosomes, (Mohamed et al. <xref ref-type="bibr" rid="CR15">2007</xref>). Among others, chromosome 19 has been found to gain material in patients with multiple myeloma, and the chromosomal region 19q13 was found to be a typical breakpoint region in translocation processes (Nilsson et al. <xref ref-type="bibr" rid="CR16">2003</xref>). Importantly, the microRNA-cluster miR-371-3 is located on the long arm of chromosome 19 (19q13.4) in immediate vicinity to the breakpoint region. Thus, it appears conceivable that due to chromosomal rearrangements, the miR 371-3 cluster has been activated in at least a certain number of patients with multiple myeloma. Similar observations have already been made in thyroid adenomas (Rippe et al. <xref ref-type="bibr" rid="CR19">2010</xref>).</p><p id="Par18">Clearly, the hypothesis that M371 serum level elevation in patients with multiple myeloma may be caused by cancer-related chromosome 19 alterations remains unproven because we do not have information on cytogenetic analyses in these patients. As yet, the frequency of that event is not clear, because only 5 patients have been evaluated so far. Further, any associations of M371 expression with oncological stages and other clinical features remain unknown. Nonetheless, 3 out of 5 patients having elevated expression of M371 appears to be more than a chance finding and consecutively, a possible expression of M371 in a number of patients with multiple myeloma should be considered upon clinical application of the test. Further investigation of elevated M371 levels in multiple myeloma patients is required preferably with employing digital-droplet PCR which could afford a more precise measurement than the PCR method used herein.</p><p id="Par19">If multiple myeloma is excluded from the analysis, the relative frequency of M371 expression in NTMs would only be 3.8% (5/132). This frequency is still somewhat higher than the zero expression rate found in tumour-free controls in the present study. However, this null finding is probably related to the small sample size of controls. Low frequencies of M371 level elevations in healthy males (around 3&#x02013;5%) had been found in two previous studies (Dieckmann et al. <xref ref-type="bibr" rid="CR3">2017a</xref>, <xref ref-type="bibr" rid="CR4">b</xref>, <xref ref-type="bibr" rid="CR5">2019</xref>) where considerably larger control groups were employed. Accordingly, there is settled evidence for serum level elevations of this miR in very few individuals of the healthy male population. The 3.8% frequency in nontesticular cancers found herein, closely aligns with M371 elevations found in healthy controls previously. In consequence, false-positive rates are obviously almost identical in healthy controls and in other malignancies. This view is probably underlined by the only modest extents of M371 serum level elevations in NTMs. The base-line M371 expression rate of &#x0003c;&#x02009;5% in NTMs (with multiple myeloma excluded) appears to be of little clinical relevance.</p><p id="Par20">The very low false-positive rate of M371 documented in the present series unveils some minor analogies with the established serum tumour markers of GCT, human beta chorionic gonadotropin (bHCG) and alpha fetoprotein (AFP). Both of the traditional marker substances are likewise expressed in several nontesticular health conditions. In particular, they are highly elevated in maternal serum during early pregnancy, and accordingly, bHCG and AFP are routinely used for monitoring pregnancy. Furthermore, bHCG is highly elevated in gestational trophoblastic neoplasia, and sporadic elevations occur in a number of other cancers (Pedrazzoli et al. <xref ref-type="bibr" rid="CR17">2021</xref>). False-positive results may occur in the presence of high levels of luteinizing hormone (LH) (Takizawa et al. <xref ref-type="bibr" rid="CR25">2017</xref>). AFP is specifically associated with hepatocellular carcinoma and may be elevated in other hepatic diseases as well (Lani et al. <xref ref-type="bibr" rid="CR11">2024</xref>). Also, around 2% of healthy males were found to have slightly elevated levels of AFP in the absence of any disease (Dieckmann et al. <xref ref-type="bibr" rid="CR3">2017a</xref>, <xref ref-type="bibr" rid="CR4">b</xref>).</p><p id="Par21">Limitations of this study mainly relate to the small number of cases with multiple myeloma and to the lack of information regarding oncological and clinical details of the cases. Control groups are still small, too, and the median age of healthy controls is considerably lower than that of patients with nontesticular malignancies. Information on serum levels of bHCG and AFP is missing. Thus, direct comparison of M371 with traditional markers is not possible.</p></sec><sec id="Sec8"><title>Conclusions</title><p id="Par22">The M371 expression rate in serum of patients with other cancers is in the range of that in healthy males. Thus, the first condition of the Lange &#x00026; Winfield criteria for valuable tumour markers is clearly fulfilled by the M371-Test (Lange and Winfield <xref ref-type="bibr" rid="CR10">1987</xref>). This miR represents a serum biomarker with an outstandingly high specificity for germ cell tumours. There is a first indication for the expression of M371 in patients with multiple myeloma. This novel information warrants further investigation including evaluation of other miRs of the cluster.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Armin Soave and Klaus-Peter Dieckmann are joint senior authorship</p></fn></fn-group><ack><title>Acknowledgements</title><p>The technical assistance of the staff of medilys laboratory at Asklepios Klinik Altona in processing blood samples is gratefully acknowledged. Thanks to Dr. Petra Anheuser, Asklepios Klinik Wandsbek, Hamburg, for contributing melanoma patients.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Study concept and design: G.B. KP.D., A.S. Acquisition of data: B.H., A.I. Analysis and interpretation of data: A.I., M.K., C.D., G.B., KP.D. Drafting of the manuscript: KP.D., G.B., M.K. Critical revision of the manuscript for important intellectual content: B.H., D.A., A.S. Statistical analysis: G.B., C.D., M.K. Administrative, technical, or material support: A.I., B.H. Supervision: H.A., C.W., A.S.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by Projekt DEAL. The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets analyzed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar23"><title>Ethical approval</title><p id="Par23">This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the The Ethical Committee of &#x000c4;rztekammer Bremen (HR/RE-301A).</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par24">Klaus-Peter Dieckmann and Gazanfer Belge possess 5.7% ownership shares of mir|detect Company, Bremerhaven, Germany. Markus Klemke is employee of mir|detect Company, Bremerhaven, Germany. All other authors declare they have no conflicts of interest with publishing this article.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR2"><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Belge</surname><given-names>G</given-names></name><name><surname>Grobelny</surname><given-names>F</given-names></name><name><surname>Radtke</surname><given-names>A</given-names></name><name><surname>Bodes</surname><given-names>J</given-names></name><name><surname>Matthies</surname><given-names>C</given-names></name><name><surname>W&#x000fc;lfing</surname><given-names>C</given-names></name><name><surname>Dieckmann</surname><given-names>KP</given-names></name></person-group><article-title>Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin</article-title><source>J Cancer Res Clin Oncol</source><year>2020</year><volume>147</volume><fpage>435</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1007/s00432-020-03429-x</pub-id><pub-id pub-id-type="pmid">33200255</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Belge G, Grobelny F, Radtke A, Bodes J, Matthies C, W&#x000fc;lfing C, Dieckmann KP (2020) Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin. J Cancer Res Clin Oncol 147:435&#x02013;443<pub-id pub-id-type="pmid">33200255</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR1"><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Belge</surname><given-names>G</given-names></name><name><surname>Dumlupinar</surname><given-names>C</given-names></name><name><surname>Nestler</surname><given-names>T</given-names></name><name><surname>Klemke</surname><given-names>M</given-names></name><name><surname>T&#x000f6;rzs&#x000f6;k</surname><given-names>P</given-names></name><name><surname>Trenti</surname><given-names>E</given-names></name><name><surname>Pichler</surname><given-names>R</given-names></name><name><surname>Loidl</surname><given-names>W</given-names></name><name><surname>Che</surname><given-names>Y</given-names></name><name><surname>Hiester</surname><given-names>A</given-names></name><name><surname>Matthies</surname><given-names>C</given-names></name><name><surname>Pichler</surname><given-names>M</given-names></name><name><surname>Paffenholz</surname><given-names>P</given-names></name><name><surname>Kluth</surname><given-names>L</given-names></name><name><surname>Wenzel</surname><given-names>M</given-names></name><name><surname>Sommer</surname><given-names>J</given-names></name><name><surname>Heinzelbecker</surname><given-names>J</given-names></name><name><surname>Schriefer</surname><given-names>P</given-names></name><name><surname>Winter</surname><given-names>A</given-names></name><name><surname>Zengerling</surname><given-names>F</given-names></name><name><surname>Kramer</surname><given-names>MW</given-names></name><name><surname>Lengert</surname><given-names>M</given-names></name><name><surname>Frey</surname><given-names>J</given-names></name><name><surname>Heidenreich</surname><given-names>A</given-names></name><name><surname>W&#x000fc;lfing</surname><given-names>C</given-names></name><name><surname>Radtke</surname><given-names>A</given-names></name><name><surname>Dieckmann</surname><given-names>KP</given-names></name></person-group><article-title>Detection of recurrence through microRNA-371a-3p serum levels in a follow-up of stage I testicular germ cell tumors in the DRKS-00019223 study</article-title><source>Clin Cancer Res</source><year>2024</year><volume>30</volume><fpage>404</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-23-0730</pub-id><pub-id pub-id-type="pmid">37967143</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Belge G, Dumlupinar C, Nestler T, Klemke M, T&#x000f6;rzs&#x000f6;k P, Trenti E, Pichler R, Loidl W, Che Y, Hiester A, Matthies C, Pichler M, Paffenholz P, Kluth L, Wenzel M, Sommer J, Heinzelbecker J, Schriefer P, Winter A, Zengerling F, Kramer MW, Lengert M, Frey J, Heidenreich A, W&#x000fc;lfing C, Radtke A, Dieckmann KP (2024) Detection of recurrence through microRNA-371a-3p serum levels in a follow-up of stage I testicular germ cell tumors in the DRKS-00019223 study. Clin Cancer Res 30:404&#x02013;412<pub-id pub-id-type="pmid">37967143</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Dieckmann</surname><given-names>KP</given-names></name><name><surname>Anheuser</surname><given-names>P</given-names></name><name><surname>Simonsen</surname><given-names>H</given-names></name><name><surname>H&#x000f6;flmayer</surname><given-names>D</given-names></name></person-group><article-title>Pure testicular seminoma with non-pathologic elevation of alpha fetoprotein: a Case Series</article-title><source>Urol Int</source><year>2017</year><volume>99</volume><fpage>353</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1159/000478706</pub-id><pub-id pub-id-type="pmid">28668957</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Dieckmann KP, Anheuser P, Simonsen H, H&#x000f6;flmayer D (2017a) Pure testicular seminoma with non-pathologic elevation of alpha fetoprotein: a Case Series. Urol Int 99:353&#x02013;357<pub-id pub-id-type="pmid">28668957</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Dieckmann</surname><given-names>KP</given-names></name><name><surname>Radke</surname><given-names>A</given-names></name><name><surname>Spiekermann</surname><given-names>M</given-names></name><name><surname>Balks</surname><given-names>T</given-names></name><name><surname>Matthies</surname><given-names>C</given-names></name><name><surname>Becker</surname><given-names>P</given-names></name><name><surname>Ruf</surname><given-names>C</given-names></name><name><surname>Oing</surname><given-names>C</given-names></name><name><surname>Oechsle</surname><given-names>K</given-names></name><name><surname>Bokemeyer</surname><given-names>C</given-names></name><name><surname>Hammel</surname><given-names>J</given-names></name><name><surname>Melchior</surname><given-names>S</given-names></name><name><surname>Wosniok</surname><given-names>W</given-names></name><name><surname>Belge</surname><given-names>G</given-names></name></person-group><article-title>Serum levels of MicroRNA 371a-3p: a sensitive and specific new biomarker for germ cell tumors</article-title><source>Eur Urol</source><year>2017</year><volume>71</volume><fpage>213</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2016.07.029</pub-id><pub-id pub-id-type="pmid">27495845</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Dieckmann KP, Radke A, Spiekermann M, Balks T, Matthies C, Becker P, Ruf C, Oing C, Oechsle K, Bokemeyer C, Hammel J, Melchior S, Wosniok W, Belge G (2017b) Serum levels of MicroRNA 371a-3p: a sensitive and specific new biomarker for germ cell tumors. Eur Urol 71:213&#x02013;220<pub-id pub-id-type="pmid">27495845</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Dieckmann</surname><given-names>KP</given-names></name><name><surname>Radtke</surname><given-names>A</given-names></name><name><surname>Geczi</surname><given-names>L</given-names></name><name><surname>Matthies</surname><given-names>C</given-names></name><name><surname>Anheuser</surname><given-names>P</given-names></name><name><surname>Eckardt</surname><given-names>U</given-names></name><name><surname>Sommer</surname><given-names>J</given-names></name><name><surname>Zengerling</surname><given-names>F</given-names></name><name><surname>Trenti</surname><given-names>E</given-names></name><name><surname>Pichler</surname><given-names>R</given-names></name><name><surname>Belz</surname><given-names>H</given-names></name><name><surname>Zastrow</surname><given-names>S</given-names></name><name><surname>Winter</surname><given-names>A</given-names></name><name><surname>Melchior</surname><given-names>S</given-names></name><name><surname>Hammel</surname><given-names>J</given-names></name><name><surname>Kranz</surname><given-names>J</given-names></name><name><surname>Bolten</surname><given-names>M</given-names></name><name><surname>Krege</surname><given-names>S</given-names></name><name><surname>Haben</surname><given-names>B</given-names></name><name><surname>Loidl</surname><given-names>W</given-names></name><name><surname>Ruf</surname><given-names>CG</given-names></name><name><surname>Heinzelbecker</surname><given-names>J</given-names></name><name><surname>Heidenreich</surname><given-names>A</given-names></name><name><surname>Cremers</surname><given-names>JF</given-names></name><name><surname>Oing</surname><given-names>C</given-names></name><name><surname>Hermanns</surname><given-names>T</given-names></name><name><surname>Fankhauser</surname><given-names>CD</given-names></name><name><surname>Gillessen</surname><given-names>S</given-names></name><name><surname>Reichegger</surname><given-names>H</given-names></name><name><surname>Cathomas</surname><given-names>R</given-names></name><name><surname>Pichler</surname><given-names>M</given-names></name><name><surname>Hentrich</surname><given-names>M</given-names></name><name><surname>Eredics</surname><given-names>K</given-names></name><name><surname>Lorch</surname><given-names>A</given-names></name><name><surname>W&#x000fc;lfing</surname><given-names>C</given-names></name><name><surname>Peine</surname><given-names>S</given-names></name><name><surname>Wosniok</surname><given-names>W</given-names></name><name><surname>Bokemeyer</surname><given-names>C</given-names></name><name><surname>Belge</surname><given-names>G</given-names></name></person-group><article-title>Serum levels of microRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell-tumors: results of a prospective multicentric study</article-title><source>J Clin Oncol</source><year>2019</year><volume>37</volume><fpage>1412</fpage><lpage>1423</lpage><pub-id pub-id-type="doi">10.1200/JCO.18.01480</pub-id><pub-id pub-id-type="pmid">30875280</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R, Belz H, Zastrow S, Winter A, Melchior S, Hammel J, Kranz J, Bolten M, Krege S, Haben B, Loidl W, Ruf CG, Heinzelbecker J, Heidenreich A, Cremers JF, Oing C, Hermanns T, Fankhauser CD, Gillessen S, Reichegger H, Cathomas R, Pichler M, Hentrich M, Eredics K, Lorch A, W&#x000fc;lfing C, Peine S, Wosniok W, Bokemeyer C, Belge G (2019) Serum levels of microRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell-tumors: results of a prospective multicentric study. J Clin Oncol 37:1412&#x02013;1423<pub-id pub-id-type="pmid">30875280</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Fankhauser</surname><given-names>CD</given-names></name><name><surname>Christiansen</surname><given-names>AJ</given-names></name><name><surname>Rothermundt</surname><given-names>C</given-names></name><name><surname>Cathomas</surname><given-names>R</given-names></name><name><surname>Wettstein</surname><given-names>MS</given-names></name><name><surname>Grossmann</surname><given-names>NC</given-names></name><name><surname>Grogg</surname><given-names>JB</given-names></name><name><surname>Templeton</surname><given-names>AJ</given-names></name><name><surname>Hirschi-Blickenstorfer</surname><given-names>A</given-names></name><name><surname>Lorch</surname><given-names>A</given-names></name><name><surname>Gillessen</surname><given-names>S</given-names></name><name><surname>Moch</surname><given-names>H</given-names></name><name><surname>Beyer</surname><given-names>J</given-names></name><name><surname>Hermanns</surname><given-names>T</given-names></name></person-group><article-title>Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours</article-title><source>Br J Cancer</source><year>2022</year><volume>126</volume><fpage>1140</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1038/s41416-021-01643-z</pub-id><pub-id pub-id-type="pmid">34912073</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Fankhauser CD, Christiansen AJ, Rothermundt C, Cathomas R, Wettstein MS, Grossmann NC, Grogg JB, Templeton AJ, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, Hermanns T (2022) Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. Br J Cancer 126:1140&#x02013;1144<pub-id pub-id-type="pmid">34912073</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Ji</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>MicroRNA-371a-3p promotes progression of gastric cancer by targeting TOB1</article-title><source>Cancer Lett</source><year>2019</year><volume>443</volume><fpage>179</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2018.11.021</pub-id><pub-id pub-id-type="pmid">30529155</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Guo H, Ji F, Zhao X, Yang X, He J, Huang L, Zhang Y (2019) MicroRNA-371a-3p promotes progression of gastric cancer by targeting TOB1. Cancer Lett 443:179&#x02013;188<pub-id pub-id-type="pmid">30529155</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Lafin</surname><given-names>JT</given-names></name><name><surname>Singla</surname><given-names>N</given-names></name><name><surname>Woldu</surname><given-names>SL</given-names></name><name><surname>Lotan</surname><given-names>Y</given-names></name><name><surname>Lewis</surname><given-names>CM</given-names></name><name><surname>Majmudar</surname><given-names>K</given-names></name><name><surname>Savelyeva</surname><given-names>A</given-names></name><name><surname>Kapur</surname><given-names>P</given-names></name><name><surname>Margulis</surname><given-names>V</given-names></name><name><surname>Strand</surname><given-names>DW</given-names></name><name><surname>Murray</surname><given-names>MJ</given-names></name><name><surname>Amatruda</surname><given-names>JF</given-names></name><name><surname>Bagrodia</surname><given-names>A</given-names></name></person-group><article-title>Serum MicroRNA-371a-3p levels predict viable germ cell tumor in Chemotherapy-na&#x000ef;ve patients undergoing Retroperitoneal Lymph Node Dissection</article-title><source>Eur Urol</source><year>2020</year><volume>77</volume><fpage>290</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2019.10.005</pub-id><pub-id pub-id-type="pmid">31699528</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Lafin JT, Singla N, Woldu SL, Lotan Y, Lewis CM, Majmudar K, Savelyeva A, Kapur P, Margulis V, Strand DW, Murray MJ, Amatruda JF, Bagrodia A (2020) Serum MicroRNA-371a-3p levels predict viable germ cell tumor in Chemotherapy-na&#x000ef;ve patients undergoing Retroperitoneal Lymph Node Dissection. Eur Urol 77:290&#x02013;292<pub-id pub-id-type="pmid">31699528</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>La&#x000ef;</surname><given-names>JL</given-names></name><name><surname>Zandecki</surname><given-names>M</given-names></name><name><surname>Mary</surname><given-names>JY</given-names></name><name><surname>Bernardi</surname><given-names>F</given-names></name><name><surname>Izydorczyk</surname><given-names>V</given-names></name><name><surname>Flactif</surname><given-names>M</given-names></name><name><surname>Morel</surname><given-names>P</given-names></name><name><surname>Jouet</surname><given-names>JP</given-names></name><name><surname>Bauters</surname><given-names>F</given-names></name><name><surname>Facon</surname><given-names>T</given-names></name></person-group><article-title>Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis</article-title><source>Blood</source><year>1995</year><volume>85</volume><fpage>2490</fpage><lpage>2497</lpage><pub-id pub-id-type="doi">10.1182/blood.V85.9.2490.bloodjournal8592490</pub-id><pub-id pub-id-type="pmid">7537117</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">La&#x000ef; JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F, Facon T (1995) Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 85:2490&#x02013;2497<pub-id pub-id-type="pmid">7537117</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>PH</given-names></name><name><surname>Winfield</surname><given-names>HN</given-names></name></person-group><article-title>Biological markers in urologic cancer</article-title><source>Cancer</source><year>1987</year><volume>60</volume><fpage>464</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(19870801)60:3+&#x0003c;464::AID-CNCR2820601506&#x0003e;3.0.CO;2-C</pub-id><pub-id pub-id-type="pmid">3036331</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Lange PH, Winfield HN (1987) Biological markers in urologic cancer. Cancer 60:464&#x02013;472<pub-id pub-id-type="pmid">3036331</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Lani</surname><given-names>L</given-names></name><name><surname>Stefanini</surname><given-names>B</given-names></name><name><surname>Trevisani</surname><given-names>F</given-names></name></person-group><article-title>Surveillance for Hepatocellular Carcinoma in patients with successfully treated viral disease of the liver: a systematic review</article-title><source>Liver Cancer</source><year>2024</year><volume>13</volume><fpage>376</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1159/000535497</pub-id><pub-id pub-id-type="pmid">39114761</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Lani L, Stefanini B, Trevisani F (2024) Surveillance for Hepatocellular Carcinoma in patients with successfully treated viral disease of the liver: a systematic review. Liver Cancer 13:376&#x02013;388<pub-id pub-id-type="pmid">39114761</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Le&#x000e3;o</surname><given-names>R</given-names></name><name><surname>Albersen</surname><given-names>M</given-names></name><name><surname>Looijenga</surname><given-names>LHJ</given-names></name><name><surname>Tandstad</surname><given-names>T</given-names></name><name><surname>Kollmannsberger</surname><given-names>C</given-names></name><name><surname>Murray</surname><given-names>MJ</given-names></name><name><surname>Culine</surname><given-names>S</given-names></name><name><surname>Coleman</surname><given-names>N</given-names></name><name><surname>Belge</surname><given-names>G</given-names></name><name><surname>Hamilton</surname><given-names>RJ</given-names></name><name><surname>Dieckmann</surname><given-names>KP</given-names></name></person-group><article-title>Circulating MicroRNAs, the Next-Generation serum biomarkers in testicular germ cell tumours: a systematic review</article-title><source>Eur Urol</source><year>2021</year><volume>80</volume><fpage>456</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2021.06.006</pub-id><pub-id pub-id-type="pmid">34175151</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Le&#x000e3;o R, Albersen M, Looijenga LHJ, Tandstad T, Kollmannsberger C, Murray MJ, Culine S, Coleman N, Belge G, Hamilton RJ, Dieckmann KP (2021) Circulating MicroRNAs, the Next-Generation serum biomarkers in testicular germ cell tumours: a systematic review. Eur Urol 80:456&#x02013;466<pub-id pub-id-type="pmid">34175151</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method</article-title><source>Methods</source><year>2001</year><volume>25</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402&#x02013;408<pub-id pub-id-type="pmid">11846609</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Lobo</surname><given-names>J</given-names></name><name><surname>Le&#x000e3;o</surname><given-names>R</given-names></name><name><surname>Gillis</surname><given-names>AJM</given-names></name><name><surname>van den Berg</surname><given-names>A</given-names></name><name><surname>Anson-Cartwright</surname><given-names>L</given-names></name><name><surname>Atenafu</surname><given-names>EG</given-names></name><name><surname>Kuhathaas</surname><given-names>K</given-names></name><name><surname>Chung</surname><given-names>P</given-names></name><name><surname>Hansen</surname><given-names>A</given-names></name><name><surname>Bedard</surname><given-names>PL</given-names></name><name><surname>Jewett</surname><given-names>MAS</given-names></name><name><surname>Warde</surname><given-names>P</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>M</given-names></name><name><surname>Sweet</surname><given-names>J</given-names></name><name><surname>Looijenga</surname><given-names>LHJ</given-names></name><name><surname>Hamilton</surname><given-names>RJ</given-names></name></person-group><article-title>Utility of serum miR-371a-3p in Predicting Relapse on Surveillance in patients with clinical stage I testicular germ cell Cancer</article-title><source>Eur Urol Oncol</source><year>2021</year><volume>4</volume><fpage>483</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1016/j.euo.2020.11.004</pub-id><pub-id pub-id-type="pmid">33288479</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Lobo J, Le&#x000e3;o R, Gillis AJM, van den Berg A, Anson-Cartwright L, Atenafu EG, Kuhathaas K, Chung P, Hansen A, Bedard PL, Jewett MAS, Warde P, O&#x02019;Malley M, Sweet J, Looijenga LHJ, Hamilton RJ (2021) Utility of serum miR-371a-3p in Predicting Relapse on Surveillance in patients with clinical stage I testicular germ cell Cancer. Eur Urol Oncol 4:483&#x02013;491<pub-id pub-id-type="pmid">33288479</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Mohamed</surname><given-names>AN</given-names></name><name><surname>Bentley</surname><given-names>G</given-names></name><name><surname>Bonnett</surname><given-names>ML</given-names></name><name><surname>Zonder</surname><given-names>J</given-names></name><name><surname>Al-Katib</surname><given-names>A</given-names></name></person-group><article-title>Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes</article-title><source>Am J Hematol</source><year>2007</year><volume>82</volume><fpage>1080</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1002/ajh.20998</pub-id><pub-id pub-id-type="pmid">17654686</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Mohamed AN, Bentley G, Bonnett ML, Zonder J, Al-Katib A (2007) Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes. Am J Hematol 82:1080&#x02013;1087<pub-id pub-id-type="pmid">17654686</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>T</given-names></name><name><surname>H&#x000f6;glund</surname><given-names>M</given-names></name><name><surname>Lenhoff</surname><given-names>S</given-names></name><name><surname>Rylander</surname><given-names>L</given-names></name><name><surname>Turesson</surname><given-names>I</given-names></name><name><surname>Westin</surname><given-names>J</given-names></name><name><surname>Mitelman</surname><given-names>F</given-names></name><name><surname>Johansson</surname><given-names>B</given-names></name></person-group><article-title>A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences</article-title><source>Br J Haematol</source><year>2003</year><volume>120</volume><fpage>960</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2141.2003.04221.x</pub-id><pub-id pub-id-type="pmid">12648065</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Nilsson T, H&#x000f6;glund M, Lenhoff S, Rylander L, Turesson I, Westin J, Mitelman F, Johansson B (2003) A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences. Br J Haematol 120:960&#x02013;699<pub-id pub-id-type="pmid">12648065</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Pedrazzoli</surname><given-names>P</given-names></name><name><surname>Rosti</surname><given-names>G</given-names></name><name><surname>Soresini</surname><given-names>E</given-names></name><name><surname>Ciani</surname><given-names>S</given-names></name><name><surname>Secondino</surname><given-names>S</given-names></name></person-group><article-title>Serum tumour markers in germ cell tumours: from diagnosis to cure</article-title><source>Crit Rev Oncol Hematol</source><year>2021</year><volume>159</volume><fpage>103224</fpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2021.103224</pub-id><pub-id pub-id-type="pmid">33493632</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Pedrazzoli P, Rosti G, Soresini E, Ciani S, Secondino S (2021) Serum tumour markers in germ cell tumours: from diagnosis to cure. Crit Rev Oncol Hematol 159:103224<pub-id pub-id-type="pmid">33493632</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Radtke</surname><given-names>A</given-names></name><name><surname>Hennig</surname><given-names>F</given-names></name><name><surname>Ikogho</surname><given-names>R</given-names></name><name><surname>Hammel</surname><given-names>J</given-names></name><name><surname>Anheuser</surname><given-names>P</given-names></name><name><surname>W&#x000fc;lfing</surname><given-names>C</given-names></name><name><surname>Belge</surname><given-names>G</given-names></name><name><surname>Dieckmann</surname><given-names>KP</given-names></name></person-group><article-title>The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, has a very Rapid Decay in patients with clinical stage 1</article-title><source>Urol int</source><year>2018</year><volume>100</volume><fpage>470</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1159/000488771</pub-id><pub-id pub-id-type="pmid">29698973</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Radtke A, Hennig F, Ikogho R, Hammel J, Anheuser P, W&#x000fc;lfing C, Belge G, Dieckmann KP (2018) The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, has a very Rapid Decay in patients with clinical stage 1. Urol int 100:470&#x02013;475<pub-id pub-id-type="pmid">29698973</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Rippe</surname><given-names>V</given-names></name><name><surname>Dittberner</surname><given-names>L</given-names></name><name><surname>Lorenz</surname><given-names>VN</given-names></name><name><surname>Drieschner</surname><given-names>N</given-names></name><name><surname>Nimzyk</surname><given-names>R</given-names></name><name><surname>Sendt</surname><given-names>W</given-names></name><name><surname>Junker</surname><given-names>K</given-names></name><name><surname>Belge</surname><given-names>G</given-names></name><name><surname>Bullerdiek</surname><given-names>J</given-names></name></person-group><article-title>The two stem cell MicroRNA gene clusters C19MC and mir-371-3 are activated by specific chromosomal rearrangements in a subgroup of thyroid adenomas</article-title><source>PlosOne PLoS One</source><year>2010</year><volume>5</volume><fpage>e9485</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0009485</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Rippe V, Dittberner L, Lorenz VN, Drieschner N, Nimzyk R, Sendt W, Junker K, Belge G, Bullerdiek J (2010) The two stem cell MicroRNA gene clusters C19MC and mir-371-3 are activated by specific chromosomal rearrangements in a subgroup of thyroid adenomas. PlosOne PLoS One 5:e9485</mixed-citation></citation-alternatives></ref><ref id="CR20"><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Seales</surname><given-names>CL</given-names></name><name><surname>Puri</surname><given-names>D</given-names></name><name><surname>Yodkhunnatham</surname><given-names>N</given-names></name><name><surname>Pandit</surname><given-names>K</given-names></name><name><surname>Yuen</surname><given-names>K</given-names></name><name><surname>Murray</surname><given-names>S</given-names></name><name><surname>Smitham</surname><given-names>J</given-names></name><name><surname>Lafin</surname><given-names>JT</given-names></name><name><surname>Bagrodia</surname><given-names>A</given-names></name></person-group><article-title>Advancing GCT management: a review of miR-371a-3p and other miRNAs in comparison to traditional serum tumor markers</article-title><source>Cancers (Basel)</source><year>2024</year><volume>16</volume><fpage>1379</fpage><pub-id pub-id-type="doi">10.3390/cancers16071379</pub-id><pub-id pub-id-type="pmid">38611057</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Seales CL, Puri D, Yodkhunnatham N, Pandit K, Yuen K, Murray S, Smitham J, Lafin JT, Bagrodia A (2024) Advancing GCT management: a review of miR-371a-3p and other miRNAs in comparison to traditional serum tumor markers. Cancers (Basel) 16:1379<pub-id pub-id-type="pmid">38611057</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Seelemeyer</surname><given-names>F</given-names></name><name><surname>Pfister</surname><given-names>D</given-names></name><name><surname>Pappesch</surname><given-names>R</given-names></name><name><surname>Merkelbach-Bruse</surname><given-names>S</given-names></name><name><surname>Paffenholz</surname><given-names>P</given-names></name><name><surname>Heidenreich</surname><given-names>A</given-names></name></person-group><article-title>Evaluation of a miRNA-371a-3p assay for Predicting final histopathology in patients undergoing primary nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma</article-title><source>Eur Urol Oncol</source><year>2024</year><volume>7</volume><fpage>319</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/j.euo.2023.10.021</pub-id><pub-id pub-id-type="pmid">37932157</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Seelemeyer F, Pfister D, Pappesch R, Merkelbach-Bruse S, Paffenholz P, Heidenreich A (2024) Evaluation of a miRNA-371a-3p assay for Predicting final histopathology in patients undergoing primary nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma. Eur Urol Oncol 7:319&#x02013;322<pub-id pub-id-type="pmid">37932157</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>JA</given-names></name><name><surname>Khattak</surname><given-names>S</given-names></name><name><surname>Rauf</surname><given-names>MA</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name></person-group><article-title>Potential biomarkers of mir-371-373 gene cluster in Tumorigenesis</article-title><source>Life (Basel)</source><year>2021</year><volume>11</volume><fpage>984</fpage><pub-id pub-id-type="pmid">34575133</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Shah JA, Khattak S, Rauf MA, Cai Y, Jin J (2021) Potential biomarkers of mir-371-373 gene cluster in Tumorigenesis. Life (Basel) 11:984<pub-id pub-id-type="pmid">34575133</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Spiekermann</surname><given-names>M</given-names></name><name><surname>Belge</surname><given-names>G</given-names></name><name><surname>Winter</surname><given-names>N</given-names></name><name><surname>Ikogho</surname><given-names>R</given-names></name><name><surname>Balks</surname><given-names>T</given-names></name><name><surname>Bullerdiek</surname><given-names>J</given-names></name><name><surname>Dieckmann</surname><given-names>KP</given-names></name></person-group><article-title>MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker</article-title><source>Andrology</source><year>2015</year><volume>3</volume><fpage>78</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1111/j.2047-2927.2014.00269.x</pub-id><pub-id pub-id-type="pmid">25187505</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Spiekermann M, Belge G, Winter N, Ikogho R, Balks T, Bullerdiek J, Dieckmann KP (2015) MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker. Andrology 3:78&#x02013;84<pub-id pub-id-type="pmid">25187505</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Syring</surname><given-names>I</given-names></name><name><surname>Bartels</surname><given-names>J</given-names></name><name><surname>Holdenrieder</surname><given-names>S</given-names></name><name><surname>Kristiansen</surname><given-names>G</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>SC</given-names></name><name><surname>Ellinger</surname><given-names>J</given-names></name></person-group><article-title>Circulating serum microRNA (miR-367-3p, miR-371a-3p, miR-372-3p, miR-373-3p) as biomarkers for patients with testicular germ cell cancers</article-title><source>J Urol</source><year>2015</year><volume>193</volume><fpage>331</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2014.07.010</pub-id><pub-id pub-id-type="pmid">25046619</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Syring I, Bartels J, Holdenrieder S, Kristiansen G, M&#x000fc;ller SC, Ellinger J (2015) Circulating serum microRNA (miR-367-3p, miR-371a-3p, miR-372-3p, miR-373-3p) as biomarkers for patients with testicular germ cell cancers. J Urol 193:331&#x02013;337<pub-id pub-id-type="pmid">25046619</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Takizawa</surname><given-names>A</given-names></name><name><surname>Kawai</surname><given-names>K</given-names></name><name><surname>Kawahara</surname><given-names>T</given-names></name><name><surname>Kojima</surname><given-names>T</given-names></name><name><surname>Maruyama</surname><given-names>S</given-names></name><name><surname>Shinohara</surname><given-names>N</given-names></name><name><surname>Akamatsu</surname><given-names>S</given-names></name><name><surname>Kamba</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Ukimura</surname><given-names>O</given-names></name><name><surname>Jikuya</surname><given-names>R</given-names></name><name><surname>Kishida</surname><given-names>T</given-names></name><name><surname>Kakimoto</surname><given-names>K</given-names></name><name><surname>Nishimura</surname><given-names>K</given-names></name><name><surname>Harabayashi</surname><given-names>T</given-names></name><name><surname>Nagamori</surname><given-names>S</given-names></name><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Arai</surname><given-names>Y</given-names></name><name><surname>Sawada</surname><given-names>Y</given-names></name><name><surname>Sekido</surname><given-names>N</given-names></name><name><surname>Kinoshita</surname><given-names>H</given-names></name><name><surname>Matsuda</surname><given-names>T</given-names></name><name><surname>Nakagawa</surname><given-names>T</given-names></name><name><surname>Homma</surname><given-names>Y</given-names></name><name><surname>Nishiyama</surname><given-names>H</given-names></name></person-group><article-title>The usefulness of testosterone administration in identifying false-positive elevation of serum human chorionic gonadotropin in patients with germ cell tumor</article-title><source>J Cancer Res Clin Oncol</source><year>2017</year><volume>144</volume><fpage>109</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1007/s00432-017-2520-5</pub-id><pub-id pub-id-type="pmid">28905168</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Takizawa A, Kawai K, Kawahara T, Kojima T, Maruyama S, Shinohara N, Akamatsu S, Kamba T, Nakamura T, Ukimura O, Jikuya R, Kishida T, Kakimoto K, Nishimura K, Harabayashi T, Nagamori S, Yamashita S, Arai Y, Sawada Y, Sekido N, Kinoshita H, Matsuda T, Nakagawa T, Homma Y, Nishiyama H (2017) The usefulness of testosterone administration in identifying false-positive elevation of serum human chorionic gonadotropin in patients with germ cell tumor. J Cancer Res Clin Oncol 144:109&#x02013;115<pub-id pub-id-type="pmid">28905168</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>van Agthoven</surname><given-names>T</given-names></name><name><surname>Looijenga</surname><given-names>LH</given-names></name></person-group><article-title>Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test)</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>58037</fpage><lpage>58049</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.10867</pub-id><pub-id pub-id-type="pmid">28938535</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">van Agthoven T, Looijenga LH (2017) Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test). Oncotarget 8:58037&#x02013;58049<pub-id pub-id-type="pmid">28938535</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Jing</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>LncRNA NR2F1-AS1 regulates miR-371a-3p/TOB1 Axis to suppress proliferation of Colorectal Cancer cells</article-title><source>Cancer Biother Radiopharm</source><year>2020</year><volume>35</volume><fpage>760</fpage><lpage>764</lpage><pub-id pub-id-type="pmid">32407174</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Wang J, Dong S, Zhang J, Jing D, Wang W, Dong L, Zhao Y (2020) LncRNA NR2F1-AS1 regulates miR-371a-3p/TOB1 Axis to suppress proliferation of Colorectal Cancer cells. Cancer Biother Radiopharm 35:760&#x02013;764<pub-id pub-id-type="pmid">32407174</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>